WONOEP appraisal: Targeted therapy development for early onset epilepsies

Area of Science:

• Neuroscience and Genetics
• Epilepsy Research

Background:

• Early onset epilepsies are a diverse group of disorders often leading to drug-resistant seizures, developmental delays, and other severe comorbidities.
• Advances in genetic sequencing have identified numerous causative genes, with de novo variants being a major factor in disease etiology.
• Current therapeutic options for these conditions are limited, highlighting the need for innovative treatment strategies.

Purpose of the Study:

• To summarize novel therapeutic strategies discussed at the Workshop on Neurobiology of Epilepsy (WONOEP XVI).
• To highlight advancements in precision medicine for the targeted treatment of early onset epilepsies.

Main Methods:

• Review of presentations and discussions from WONOEP XVI focusing on emerging therapies.
• Exploration of genetic findings through gene panels, whole exome, and whole genome sequencing.
• Discussion of various therapeutic targets including molecular, cellular, and genetic approaches.

Main Results:

• Identification of genetic underpinnings for a subset of early onset epilepsy patients.
• Exploration of specific therapeutic avenues: chloride transporter inhibitors for neonatal seizures, orexinergic signaling for childhood absence epilepsy, and energy metabolism targets for Dravet syndrome.
• Consideration of cannabinoid receptor type 2, acetylcholinesterase inhibitors, cell therapies, and RNA-based therapies for early life epilepsies.

Conclusions:

• Precision medicine approaches, including small molecules and genetic therapies, show promise for treating early onset epilepsies.
• Ongoing research into novel therapeutic strategies offers hope for improved outcomes in patients with these complex neurological disorders.
• The identification of genetic bases is crucial for developing targeted and effective treatments.